JP2019527555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527555A5 JP2019527555A5 JP2019505220A JP2019505220A JP2019527555A5 JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5 JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- amino acids
- polypeptide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 254
- 150000001413 amino acids Chemical class 0.000 claims 125
- 229920001184 polypeptide Polymers 0.000 claims 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 9
- 238000003259 recombinant expression Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199878A JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| US62/369,883 | 2016-08-02 | ||
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Division JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527555A JP2019527555A (ja) | 2019-10-03 |
| JP2019527555A5 true JP2019527555A5 (enExample) | 2020-09-10 |
| JP6993402B2 JP6993402B2 (ja) | 2022-02-03 |
Family
ID=59564253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Active JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (enExample) |
| EP (2) | EP3494133B1 (enExample) |
| JP (4) | JP6993402B2 (enExample) |
| KR (1) | KR102527052B1 (enExample) |
| CN (2) | CN118063591A (enExample) |
| AU (2) | AU2017306038B2 (enExample) |
| CA (1) | CA3032870A1 (enExample) |
| DK (1) | DK3494133T3 (enExample) |
| ES (1) | ES2928051T3 (enExample) |
| HR (1) | HRP20221183T1 (enExample) |
| HU (1) | HUE060121T2 (enExample) |
| IL (2) | IL301894B2 (enExample) |
| LT (1) | LT3494133T (enExample) |
| PL (1) | PL3494133T3 (enExample) |
| PT (1) | PT3494133T (enExample) |
| RS (1) | RS63615B1 (enExample) |
| SG (2) | SG11201900654QA (enExample) |
| SI (1) | SI3494133T1 (enExample) |
| SM (1) | SMT202200379T1 (enExample) |
| WO (1) | WO2018026691A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3494133T (lt) * | 2016-08-02 | 2022-12-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t ląstelės receptoriai |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| SG11202002425PA (en) | 2017-09-20 | 2020-04-29 | The United States Of America As Represented By The Secretary | Hla class ii-restricted t cell receptors against mutated ras |
| AU2018345400B2 (en) | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| US20220088190A1 (en) * | 2019-01-25 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Targeting Mutant RAS |
| GB2596461B (en) * | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| US20220409711A1 (en) * | 2019-11-05 | 2022-12-29 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| US20230272038A1 (en) * | 2020-07-13 | 2023-08-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted drb t cell receptors against ras with g12d mutation |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| JP2023551204A (ja) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
| JP2023551819A (ja) * | 2020-11-25 | 2023-12-13 | ジーニアス・バイオテクノロジー・インコーポレイテッド | 抗原特異的ｔ細胞並びにその作製及び使用方法 |
| US20240175047A1 (en) | 2021-02-25 | 2024-05-30 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| JP2025524005A (ja) * | 2022-07-22 | 2025-07-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 養子免疫療法のための亢進された機能を有するｃｄ３発現ナチュラルキラー細胞 |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| CN120693174A (zh) * | 2022-12-13 | 2025-09-23 | 百欧恩泰美国公司 | T细胞受体构建体及其用途 |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| WO2008089053A2 (en) | 2007-01-12 | 2008-07-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| EP2749642A4 (en) * | 2011-11-30 | 2015-03-04 | Nat Cancer Ct | INDUCED MALIGNE STEM CELLS |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| PL3223850T3 (pl) | 2014-11-26 | 2020-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t przeciwko zmutowanemu kras |
| EP3901169A1 (en) | 2015-09-15 | 2021-10-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing hla-cw8 restricted mutated kras |
| LT3494133T (lt) * | 2016-08-02 | 2022-12-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t ląstelės receptoriai |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527555A5 (enExample) | ||
| HRP20221183T1 (hr) | T-stanični receptori anti-kras-g12d | |
| Walker et al. | Yeast eIF4B binds to the head of the 40S ribosomal subunit and promotes mRNA recruitment through its N-terminal and internal repeat domains | |
| JP2020534828A5 (enExample) | ||
| Mo et al. | Targeting Ubc9 for cancer therapy | |
| Fournier et al. | Recruitment of RED-SMU1 complex by Influenza A Virus RNA polymerase to control Viral mRNA splicing | |
| CN100400657C (zh) | 磷酸激酶及其应用 | |
| JP2011188853A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| Xu et al. | Sug1 modulates yeast transcription activation by Cdc68 | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| CN114045335A (zh) | circSpred1基因作为标志物在纤维化肝脏、肝癌的诊断和药物制备中的应用 | |
| Kominami et al. | Protein kinase activity associated with the IME 2 gene product, a meiotic inducer in the yeast Saccharomyces cerevisiae | |
| Mondragon et al. | TrmB family transcription factor as a thiol-based regulator of oxidative stress response | |
| Yan et al. | SUMOylation of W or1 by a novel SUMO E 3 ligase controls cell fate in C andida albicans | |
| Auvray et al. | HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4 | |
| Jacobsen et al. | Interaction between mating-type proteins from the homothallic fungus Sordaria macrospora | |
| JP2020127419A5 (enExample) | ||
| CN104193826B (zh) | 一种融合多肽及其在制备抗肿瘤药物中的应用 | |
| CN103255113B (zh) | 一种发形霞水母过氧化物还原酶及其编码基因与应用 | |
| CN114957491A (zh) | 一种靶向结合β-catenin蛋白的多肽、多肽衍生物及其应用 | |
| CN103665141B (zh) | 与艰难梭菌细胞毒素b相互作用的蛋白 | |
| JP2017525357A5 (enExample) | ||
| CN101928335B (zh) | 一种真菌抗肿瘤多肽核苷酸序列及制备方法和应用 | |
| CN102808016B (zh) | Arid1a基因及其编码蛋白产物的应用 |